Bropirimine
CAS: 56741-95-8
Ref. 3D-FB19342
| 1g | Discontinued | ||
| 50mg | Discontinued | ||
| 100mg | Discontinued | ||
| 250mg | Discontinued | ||
| 500mg | Discontinued |
Product Information
- 2-Amino-5-bromo-6-phenyl-4(3H)-pyrimidinone5-Bromo-6-phenylisocytosine2-Amino-5-bromo-6-phenyl-4-pyrimidinol
- 2-Amino-5-bromo-4-hydroxy-6-phenylpyrimidine
- 2-Amino-5-bromo-6-phenyl-1H-pyrimidin-4-one
- 2-Amino-5-bromo-6-phenyl-3,4-dihydropyrimidin-4-one
- 2-Amino-5-bromo-6-phenyl-4(1H)-pyrimidinone
- 2-Amino-5-bromo-6-phenyl-4(3H)-pyrimidinone
- 2-Amino-5-bromo-6-phenyl-4-pyrimidinol
- 2-Amino-5-bromo-6-phenyl-4-pyrimidinone
- 2-Amino-5-bromo-6-phenylpyrimidin-4(1H)-one
- 2-Amino-5-bromo-6-phenylpyrimidin-4-ol
- See more synonyms
- 4(1H)-pyrimidinone, 2-amino-5-bromo-6-phenyl-
- 4(3H)-pyrimidinone, 2-amino-5-bromo-6-phenyl-
- 4-Pyrimidinol, 2-Amino-5-Bromo-6-Phenyl-
- 5-Bromo-2,3-dihydro-2-imino-6-phenyl-4(1H)-pyrimidinone
- 5-Bromo-6-phenylisocytosine
- NSC 149027
- Pnu 54461
- U 54461
- U 54461S
Bropirimine is a drug that acts as an anti-cancer agent and has been used in the treatment of autoimmune diseases. It inhibits the growth of cancer cells by binding to basic proteins, which are involved in intermolecular hydrogen bonding, and inducing apoptosis. Bropirimine also binds to toll-like receptor 4 (TLR4) and inhibits the production of inflammatory cytokines by macrophages, thereby inhibiting inflammation. Bropirimine also has metabolic effects, such as reducing blood sugar levels and improving insulin sensitivity in animal models with high blood sugar levels. The molecular pathogenesis of bropirimine is not well understood, but it may involve hydrogen bonding interactions with other molecules or structural changes to cellular proteins.
